This report draws on analysis from our fund managers, simplified as
far as the subject matter allows. Market
conditions this cycle remain unprecedented within living memory for most
investors, and there is a considerable amount to weigh when balancing a
portfolio through it. I will not insult
anyone’s intelligence by pretending otherwise.
The Delta Variant and What It Changes
The Delta variant now accounts for the overwhelming majority of new
global cases. Since the start of July
2021, the global effective reproduction number has sat above the 1.0 threshold
and continued climbing, confirming that COVID-19 transmission has returned to
exponential growth. Economic recovery,
however, remains highly policy-driven, and Delta is more likely to extend the
timeline of reopening than to reverse it outright. Critically, in countries with high
vaccination rates, hospitalisation and fatality rates remain manageable
compared to previous waves. There is no
credible reason to expect a return to the tight lockdowns of March and April
2020. Governments are structurally
incentivised toward gradual reopening even as case counts climb, because the
fiscal and political cost of another full lockdown has become considerably
higher than the cost of managing Delta in the open.
The Valuation Picture
Relative valuation continues to favour equities over bonds and
credit, and that gap has widened on the back of lower Treasury yields and
improving corporate earnings. I expect
this gap to narrow as the Federal Reserve turns hawkish on inflation and begins
raising rates. US inflation currently
sits at 4.2%, more than double the Federal Reserve’s 2% target. Every fund in our range underperformed its
benchmark last quarter, driven by a rotation from growth into value stocks that
will take time to unwind. Since inception,
however, every fund has still outperformed its respective benchmark, a direct
result of maintaining a higher equity allocation through the cycle rather than
flinching at quarterly noise.
Economic Recovery, Region by Region
Recovery remains on track across major economies, even as market
expectations recalibrate from earlier, more elevated levels. The services sector is recovering strongly at
the global level, supported by eased social distancing, active policy support,
and continued vaccine rollout. Solid
manufacturing activity should support strong growth for the remainder of the
year, and inventory restocking, once supply-chain disruptions ease, will
provide an additional tailwind.
China stands as the exception among major economies, given its
strict provincial lockdowns wherever cases appear. Hong Kong follows the same pattern. China’s growth slowdown is eroding the
first-mover advantage it built earlier in the pandemic cycle, though recent
policy actions should ease some of that pressure. The broader pattern holds regardless:
countries with high vaccination rates will diverge clearly, in both economic
performance and inflation trajectory, from countries with low vaccination rates. Vaccination remains the single variable that
matters most to the reopening timeline.
Inflation: Transitory, Not Structural
Inflationary pressure has receded over recent months and remains
elevated in only a handful of countries.
In the United States, that pressure concentrates specifically in goods
and services sensitive to COVID-19 and the reopening process itself, rather than
broad-based structural inflation. In
China, producer price inflation has likely peaked as commodity prices
stabilise, while consumer prices remain benign.
The anticipated rapid rise in inflation prints across major economies is
most plausibly transitory rather than structural.
Corporate Earnings, and Why They Matter More Than the Headlines
The first-quarter 2021 earnings season closed strongly, with over
85% of S&P 500 constituents reporting an earnings surprise, and that
momentum appears set to continue into the second quarter. Among companies reporting so far, the average
magnitude of surprise sits near 20%.
Announced share buybacks are already beating the trailing three-year
average across US markets. Together,
these factors provide meaningful tailwinds for developed market equities in an
environment still flush with liquidity.
Asian Equities: A More Complicated Picture
The outlook for Asian equities is considerably less rosy at
present. Chinese equities continue to
soften under mounting regulatory scrutiny across key sectors, compounded by
fears of cascading corporate debt defaults tied to the impending collapse of
the Evergrande Group. The ongoing
structural reform of Chinese capital markets could prove positive over the long
run, but investors are pricing in a materially higher near-term risk premium in
the meantime. Outside China, sentiment
across major ASEAN markets, Singapore excepted, remains weighed down by renewed
Delta infections layered onto relatively low vaccination rates. Momentum in Taiwanese and Korean equities is
also receding as the current upcycle in electronics and chip manufacturing
becomes increasingly priced in.
Central Bank Policy: Still Accommodative, For Now
The current recovery remains highly policy-driven, and Delta
continues to extend the reopening timeline while its uncertainty weighs on
sentiment. Policymakers will need to
sustain accommodative policy for some time yet, with managing the eventual
transition away from ultra-loose settings the market’s central
preoccupation. Jerome Hayden Powell, the
sixteenth chair of the Federal Reserve, has reiterated that recent inflationary
pressure is likely transitory, and confirmed the Fed will continue discussing
tapering in upcoming meetings, with advance notice attached to any eventual
decision. The European Central Bank
remains similarly dovish, with no sign of moderating its Pandemic Emergency
Purchase Programme, and expects rates to hold at present or lower levels until
inflation reaches 2% well within its two-to-three-year forecast horizon.
In Asia Pacific, the People’s Bank of China surprised markets with
an unexpected cut to its reserve requirement ratio in July 2021, and future
guidance is expected to skew dovish as recovery continues. Beyond Delta and the idiosyncratic risks already
noted across Asia and China, other systemic risks remain on our radar. None of them, at present, appear sufficient
to derail the broader direction of relative performance between equities and
fixed income, or between developed markets and East Asia and emerging markets
within equities themselves.
Fixed Income Positioning
Treasury yields have declined recently on reduced inflation
compensation. The eventual tapering path
for asset purchases should dampen Treasury performance further. With US investment-grade default rates
sitting below historical averages, downside risk remains contained, though
upside is similarly limited given tight spreads and high sensitivity to
interest rate movement. Asian credit looks
comparatively more attractive, with spreads having widened while default risk
remains stable, and spillover risk from certain distressed Chinese corporates
appears contained rather than systemic.
Equity Positioning
Global equities should continue outperforming fixed income, led by
developed markets. Major central banks
remain accommodative for now, and any tapering discussion appears well
communicated in advance rather than sprung on markets. In the United States, reported earnings and
sales continue surprising to the upside with rising magnitude, and strong
buyback activity provides an additional tailwind. Within equities, I remain cautiously neutral
on Asia, given China’s regulatory overhang and the low vaccination rates
weighing on most ASEAN markets outside Singapore.
The Long View
Delta remains the central concern as governments adapt to living
alongside an endemic virus rather than eliminating it. Relative valuation continues to favour
equities over bonds and credit, and that gap has widened as Treasury yields
fall and earnings improve. Agility in
adding or trimming equity exposure during corrections, or for profit-taking,
remains necessary to balance return potential against risk. The very factors currently weighing on Asian
equities may well provide the entry point the region needs.
Every investment in our range is made with a long-term outlook, and
portfolio performance has delivered positive returns since inception despite
short-term volatility. Our Adventurous,
Balanced, and Conservative Funds have remained overweight equities throughout
the quarter, adding to that outperformance.
Global recovery continues to draw on the flood of liquidity from fiscal
and monetary policy, and the lifting of lockdown restrictions worldwide remains
broadly on track even after two months of rising Delta infections. Further mutations may delay recovery. They will not derail the reopening narrative
outright. Global and regional economies
cannot afford to remain closed indefinitely, and every government involved
knows it.
In Conversation with Iain McCombie, Baillie Gifford
Iain McCombie, sub-manager of the AIA Global Quality Growth Fund at
Baillie Gifford, shared his perspective on stock selection, the macroeconomic
backdrop, and short-term volatility. On
the advantage of a long-term growth thesis in the current cycle, McCombie’s
central argument is that this year has made the case against market timing and
economic forecasting better than any theoretical argument could. Early 2021 saw “re-opening” stocks come into
favour as investors bet on a sharp economic recovery, only for that enthusiasm
to fade back toward defensive names once case counts spiked again. Rather than attempt to call that pendulum
swing, which he regards as close to impossible to do consistently, the Fund
concentrates on owning a small number of exceptional growth businesses with
structural advantages, differentiated cultures, and large addressable
markets. Positioning follows bottom-up
stock selection reflecting where the most attractive growth opportunities sit
on a five-to-ten-year view, with key themes spanning the climate and energy
transition, innovative healthcare, and a new wave of technology companies
offering what McCombie calls “scale as a service”, firms such as Amazon Web
Services, Shopify, and Twilio, which lower the barriers to entrepreneurship by
levelling the playing field between the largest and smallest players.
On the risks to that thesis, McCombie acknowledged that rising
rates and inflation dominate market commentary, and for good reason: higher
discount rates typically hurt growth equities disproportionately, given how
much of their earnings sit further out on the horizon. His counterargument rests on portfolio
construction rather than macro prediction.
The Fund favours companies with strong balance sheets, net cash
positions, genuine pricing power, and market leadership, citing
subscription-based software businesses and firms such as Alibaba, Netflix, and
Amazon, all of which have demonstrated that customers tolerate price increases
when the product commands genuine loyalty.
McCombie describes the team as broadly unconcerned about a modest uptick
in rates and inflation, on the basis that their focus sits a decade out rather
than on the next earnings cycle.
On recent portfolio developments, healthcare emerges as the theme
generating the most excitement internally, tied to the broader thesis that the
21st century may prove to be biology’s century as genetic-level disease
analysis transforms medicine. McCombie
pointed to the 2020 COVID-19 vaccine race as the moment this potential entered
public consciousness, noting that Moderna, which the Fund does not hold, needed
only four days to develop its vaccine candidate, built on two days of genome
sequencing work by Illumina, a long-standing Fund holding, followed by two
further days for Moderna to apply its own technology. Alongside existing
positions in Illumina, STAAR Surgical, and Denali Therapeutics, the Fund has
taken a new stake in 10x Genomics, which builds instruments and consumables for
single-cell analysis, and added to its holding in Exact Sciences, a molecular
cancer diagnostics firm. It also holds
companies improving drug discovery efficiency, including Dassault Systèmes and
Codexis.
On identifying quality growth across Asia’s idiosyncrasies,
McCombie traced the Fund’s global outlook back to Baillie Gifford’s founding in
1908, noting that the firm’s very first investments were in Malaysian rubber
plantations, made on a bet about the growth of the American car industry. That global, open-minded posture, he argues,
still shapes how the Fund approaches China today. He is dismissive of the lazy comparisons that
dominate Western coverage of Chinese technology, casting Alibaba as “the Amazon
of China” or Meituan as “China’s Grubhub”, arguing these labels ignore both the
scale differences between the two markets and the extent to which Chinese
internet businesses are frequently leading on innovation rather than copying
it. Baillie Gifford’s research process leans on decades of cultivated
relationships spanning industry experts, market specialists, and academia,
including a sponsorship of the University of Oxford’s China Centre and a
relationship with Tsinghua University’s Computational Biology Department,
alongside a growing Shanghai investment research office intended to deepen
existing company relationships and sharpen the firm’s cultural lens on the
region’s genuine pace of innovation.
Terence Nunis | Executive Chairman, Equinox Zenith | Author,
The 1% Playbook: The Billionaire Cheat Code